SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors

Summary

This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 in combination with SCTB39G with or without standard therapy in adult patients with advanced malignant solid tumors. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.

Timeline

Start

2026-06-30

Primary completion

2029-06-30

Completion

2029-06-30

Drugs

Indications